Literature DB >> 15674412

A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias.

F Speleman1, B Cauwelier, N Dastugue, J Cools, B Verhasselt, B Poppe, N Van Roy, J Vandesompele, C Graux, A Uyttebroeck, M Boogaerts, B De Moerloose, Y Benoit, D Selleslag, J Billiet, A Robert, F Huguet, P Vandenberghe, A De Paepe, P Marynen, A Hagemeijer.   

Abstract

Chromosomal translocations with breakpoints in T-cell receptor (TCR) genes are recurrent in T-cell malignancies. These translocations involve the TCRalphadelta gene (14q11), the TCRbeta gene (7q34) and to a lesser extent the TCRgamma gene at chromosomal band 7p14 and juxtapose T-cell oncogenes next to TCR regulatory sequences leading to deregulated expression of those oncogenes. Here, we describe a new recurrent chromosomal inversion of chromosome 7, inv(7)(p15q34), in a subset of patients with T-cell acute lymphoblastic leukemia characterized by CD2 negative and CD4 positive, CD8 negative blasts. This rearrangement juxtaposes the distal part of the HOXA gene cluster on 7p15 to the TCRbeta locus on 7q34. Real time quantitative PCR analysis for all HOXA genes revealed high levels of HOXA10 and HOXA11 expression in all inv(7) positive cases. This is the first report of a recurrent chromosome rearrangement targeting the HOXA gene cluster in T-cell malignancies resulting in deregulated HOXA gene expression (particularly HOXA10 and HOXA11) and is in keeping with a previous report suggesting HOXA deregulation in MLL-rearranged T- and B cell lymphoblastic leukemia as the key factor in leukaemic transformation. Finally, our observation also supports the previous suggested role of HOXA10 and HOXA11 in normal thymocyte development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15674412     DOI: 10.1038/sj.leu.2403657

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  30 in total

Review 1.  T-cell acute lymphoblastic leukemia.

Authors:  Sabina Chiaretti; Robin Foà
Journal:  Haematologica       Date:  2009-02       Impact factor: 9.941

2.  High-resolution identification of balanced and complex chromosomal rearrangements by 4C technology.

Authors:  Marieke Simonis; Petra Klous; Irene Homminga; Robert-Jan Galjaard; Erik-Jan Rijkers; Frank Grosveld; Jules P P Meijerink; Wouter de Laat
Journal:  Nat Methods       Date:  2009-10-11       Impact factor: 28.547

Review 3.  The molecular basis of T cell acute lymphoblastic leukemia.

Authors:  Pieter Van Vlierberghe; Adolfo Ferrando
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

4.  Insulin-like growth factor 1 is a direct HOXA9 target important for hematopoietic transformation.

Authors:  J Steger; E Füller; M-P Garcia-Cuellar; K Hetzner; R K Slany
Journal:  Leukemia       Date:  2014-09-25       Impact factor: 11.528

Review 5.  The genetics and mechanisms of T cell acute lymphoblastic leukaemia.

Authors:  Laura Belver; Adolfo Ferrando
Journal:  Nat Rev Cancer       Date:  2016-07-25       Impact factor: 60.716

6.  HOXA-activated early T-cell progenitor acute lymphoblastic leukemia: predictor of poor outcome?

Authors:  Jules Pp Meijerink; Kirsten Canté-Barrett; Eric Vroegindeweij; Rob Pieters
Journal:  Haematologica       Date:  2016-06       Impact factor: 9.941

Review 7.  Molecular cytogenetics in haematological malignancy: current technology and future prospects.

Authors:  Lyndal Kearney; Sharon W Horsley
Journal:  Chromosoma       Date:  2005-10-15       Impact factor: 4.316

8.  Polycomb repressor complex 2 regulates HOXA9 and HOXA10, activating ID2 in NK/T-cell lines.

Authors:  Stefan Nagel; Letizia Venturini; Victor E Marquez; Corinna Meyer; Maren Kaufmann; Michaela Scherr; Roderick Af MacLeod; Hans G Drexler
Journal:  Mol Cancer       Date:  2010-06-17       Impact factor: 27.401

9.  The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia.

Authors:  Pieter Van Vlierberghe; Martine van Grotel; Joëlle Tchinda; Charles Lee; H Berna Beverloo; Peter J van der Spek; Andrew Stubbs; Jan Cools; Kyosuke Nagata; Maarten Fornerod; Jessica Buijs-Gladdines; Martin Horstmann; Elisabeth R van Wering; Jean Soulier; Rob Pieters; Jules P P Meijerink
Journal:  Blood       Date:  2008-02-25       Impact factor: 22.113

10.  HOX proteins and leukemia.

Authors:  Kajal V Sitwala; Monisha N Dandekar; Jay L Hess
Journal:  Int J Clin Exp Pathol       Date:  2008-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.